FiltersReset Filters

With box warnings

Without box warnings

Branded

Generic

4 results

octreotide acetate
(octreotide acetate)
Hainan Shuangcheng Pharmaceuticals Co., Ltd.
Usage: Octreotide acetate injection is indicated for reducing growth hormone and IGF-1 levels in acromegaly, treating severe diarrhea and flushing from metastatic carcinoid tumors, and managing profuse watery diarrhea from vasoactive intestinal peptide tumors (VIPomas). Clinical trials did not demonstrate improvements in tumor size or growth rate.
sandostatin lar depot
(octreotide acetate)
Novartis Pharmaceuticals Corporation
Usage: SANDOSTATIN LAR DEPOT is indicated for long-term maintenance therapy in acromegaly, and to treat severe diarrhea associated with metastatic carcinoid tumors and VIP-secreting tumors (VIPomas) in patients who have tolerated initial treatment with Sandostatin Injection.
signifor lar
(pasireotide)
Recordati Rare Diseases, Inc.
Usage: SIGNIFOR LAR is indicated for treating acromegaly in patients with inadequate surgical response or unsuitable for surgery, and for Cushing's disease when pituitary surgery is not an option or hasn't been curative.
somatuline depot
(lanreotide acetate)
Ipsen Biopharmaceuticals, Inc.
Usage: SOMATULINE DEPOT is indicated for long-term treatment of acromegaly, unresectable gastroenteropancreatic neuroendocrine tumors (GEP-NETs), and carcinoid syndrome in adults. It aims to normalize growth hormone levels, improve progression-free survival in GEP-NETs, and reduce the need for short-acting somatostatin analog rescue therapy in carcinoid syndrome.

Somatostatin Analog class drugs

octreotide acetate

sandostatin lar depot

signifor lar

somatuline depot